The Archives of Bone and Joint Surgery

The Archives of Bone and Joint Surgery

Anti-PF4/ Heparin Antibodies Early Seroconversion in Hip Fracture Patients Receiving Low Molecular Weight Heparin Prophylaxis: a Pilot Study of 100 Consecutive Patients

Document Type : RESEARCH PAPER

Authors
Markos Psifis 1
Christos Koutserimpas 2
Ioannis Stavrakakis 1
Chrysostomos Tsatsoulas 1
Vasiliki Danilatou 3
Kalliopi Alpantaki 1
1 Department of Orthopaedics and Trauma Surgery, “Venizeleion” General Hospital of Heraklion, Crete, Greece
2 Department of Anatomy, School of Medicine, Faculty of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece
3 School of Medicine, European University of Cyprus, 2404 Nicosia, Cyprus
10.22038/abjs.2025.80206.3661
Abstract
Objectives: Heparin-induced thrombocytopenia (HIT) represents a serious adverse reaction triggered by antibodies (anti-PF4/H) in heparin regimens. It is not clear if different low-molecular weight heparins (LMWHs) prompt distinct immunogenic responses in anti-PF4/H production and if these antibodies correlate with thrombocytopenia, thrombotic events, and early postoperative mortality. This pilot prospective study investigates the early output of anti-PF4/ H in elderly patients undergoing proximal femoral nailing for an intertrochanteric hip fracture surgery.
Methods: A total of 100 consecutive patients (72 females) with surgically treated intertrochanteric hip fractures were prospectively included. Ninety-four patients were available for the final follow-up. Twenty-seven patients received bemiparin, 42 enoxaparin and 25 tinzaparin. The levels of anti-PF4/H using the semi-quantitative latex-enhanced immunoassay; HemosIL® HIT-Ab(PF4-H) and platelets (PLT) levels were measured on the admission day and on day 5 following LMWH administration. Patients were followed up for at least 3 months for major thrombotic events and all-cause mortality.
Results: No patient developed clinically evident HIT, while 6 (6.4%) experienced thrombotic complications, and 22 (23.4%) passed away within 3 months after surgery. None of the patients with thrombotic complications tested positive for anti-PF4/H. Upon evaluating patients' seroconversion by day 5, six out of 94 (6.4%) patients tested positive for anti-PF4/H. Among them, three patients received bemiparin, two tinzaparin, and one enoxaparin. No statistically significant variance was observed in anti-PF4/H seroconversion between different types of LMWHs (p-value = 0.545) or in PLT count deviations (p-value = 0.990).
Conclusion: This pilot prospective study investigated anti-PF4/H production in older patients with hip fractures receiving different LMWHs. Preliminary results suggest that all tested anticoagulants have similar immunogenicity profiles in terms of PF4/H sensitization. These findings highlight the overall safety of LMWHs in elderly hip fracture patients. Moreover, the presence of anti-PF4/H appears unrelated to PLT fluctuations, subsequent VTE events and early postoperative mortality.
        Level of evidence: II
Keywords
Anti/ PF4
Femoral nail
Heparin
Hip fracture
HIT
LMWH
Subjects
  1. Koster A, Nagler M, Erdoes G, Levy JH. Heparin-induced Thrombocytopenia: Perioperative Diagnosis and Management. Anesthesiology. 2022; 136:336-344. doi: 10.1097/ALN.0000000000004090.
  2. Arepally GM, Cines DB. Pathogenesis of heparin-induced thrombocytopenia. Transl Res. 2020; 225:131-140. doi: 10.1016/j.trsl.2020.04.014.
  3. Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017; 129:2864-2872. doi: 10.1182/blood-2016-11-709873.
  4. Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood. 2010; 115:1797-803. doi: 10.1182/blood-2009-07-231506.
  5. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006; 4:759-65. doi: 10.1111/j.1538-7836.2006.01787.x.
  6. Warkentin TE. Challenges in Detecting Clinically Relevant Heparin-Induced Thrombocytopenia Antibodies. Hamostaseologie. 2020; 40:472-484. doi: 10.1055/a-1223-3329.
  7. Hamadi R, Sakr F, Aridi H, et al. Heparin-Induced Thrombocytopenia in Chronic Hemodialysis Patients. Clin Appl Thromb Hemost. 2023; 29:10760296231177993. doi: 10.1177/10760296231177993.
  8. Giles JB, Steiner HE, Rollin J, et al Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. Blood Adv. 2022; 6:4137-4146. doi: 10.1182/bloodadvances.2022007673.
  9. Warkentin TE, Cook RJ, Marder VJ, Greinacher A. Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost. 2010; 8:504-12. doi: 10.1111/j.1538-7836.2009.03735.x.
  10. Warkentin TE, Sheppard JAI, Linkins LA, Arnold DM, Nazy I. Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL® HIT-Ab (PF4-H)] for the diagnosis of immune heparin-induced thrombocytopenia. Thromb Res. 2017; 153:108-117. doi:10.1016/j.thromres.2017.03.010.
  11. Warkentin TE, Arnold DM, Sheppard JI, Moore JC, Kelton JG, Nazy I. Investigation of anti-PF4 versus anti-PF4/heparin reactivity using fluid-phase enzyme immunoassay for 4 anti-PF4 disorders: classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, vaccine-induced immune thrombotic thrombocytopenia, and spontaneous HIT. J Thromb Haemost. 2023; 21(8):2268-2276. doi: 10.1016/j.jtha.2023.04.034.
  12. Ezelsoy M, Saracoglu KT, Oral K, Saracoglu A, Akpinar B. Positive Heparin/PF4 Antibodies and High Mortality Rate: a Retrospective Case-Series Analysis. Braz J Cardiovasc Surg. 2020; 35:950-957. doi: 10.21470/1678-9741-2019-0360.
  13. Greinacher A, Warkentin TE. Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond. Hematology Am Soc Hematol Educ Program. 2023; 2023:1-10. doi: 10.1182/hematology.2023000503.
  14. Warkentin TE. Platelet-activating anti-PF4 disorders: An overview. Semin Hematol. 2022; 59:59-71. doi: 10.1053/j.seminhematol.2022.02.005.
  15. Sahu KK, Jindal V, Anderson J, Siddiqui AD, Jaiyesimi IA. Current Perspectives on Diagnostic Assays and Anti-PF4 Antibodies for the Diagnosis of Heparin-Induced Thrombocytopenia. J Blood Med. 2020; 11:267-277. doi: 10.2147/JBM.S232648.
  16. Larsen EL, Nilius H, Studt JD, et al. Accuracy of Diagnosing Heparin-Induced Thrombocytopenia. JAMA Netw Open. 2024; 7:e243786. doi: 10.1001/jamanetworkopen.2024.3786.
  17. Kelton JG, Warkentin TE, Moore JC, et al. A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins. J Thromb Haemost. 2012; 10:1446-9. doi: 10.1111/j.1538-7836.2012.04759.x.
  18. Hammerer-Lercher A, Nilius H, Studt JD, et al. Limited concordance of heparin/platelet factor 4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study. J Thromb Haemost. 2023; 21:2559-2568. doi: 10.1016/j.jtha.2023.05.016.
  19. Selleng S, Malowsky B, Itterman T, et al. Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery. Am Heart J. 2010; 160:362-9. doi: 10.1016/j.ahj.2010.05.026.
  20. Zhang R, Huang Y, Zhang M, Bai J, Liu J. Serum antibodies to the heparin/platelet factor 4 complex are an independent predictor of thrombotic complications following pediatric fontan surgery. Clin Appl Thromb Hemost. 2012; 18:448-52. doi: 10.1177/1076029612449198.
  21. Mattioli AV, Bonetti L, Carletti U, Ambrosio G, Mattioli G. Thrombotic events in patients with antiplatelet factor 4/heparin antibodies. Heart. 2009; 95:1350-4. doi: 10.1136/hrt.2008.160549.
  22. Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood. 2010; 115:1797-803. doi: 10.1182/blood-2009-07-231506.
  23. Motokawa S, Torigoshi T, Maeda Y, et al. IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics. BMC Musculoskelet Disord. 2011; 12:22. doi: 10.1186/1471-2474-12-22.
  24. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005; 106:3791-6. doi: 10.1182/blood-2005-05-1938.
  25. Griffin JW, Hopkinson WJ, Lassen MR, Thethi I, Litinas E, Fareed J. Assessment of HIT antibody complex in hip fracture patients receiving enoxaparin or unfractionated heparin. Clin Appl Thromb Hemost. 2011; 17:567-71. doi: 10.1177/1076029611398121.
  26. Liu L, Zheng H, Chen S, Wang S, Yang M. Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and

 

        pharmacovigilance assessment of the FAERS database. Front Pharmacol. 2023; 14:1247253. doi: 10.3389/fphar.2023.1247253.

  1. Hsu WW, Zhang X, Sing CW, et al. Unveiling unique clinical phenotypes of hip fracture patients and the temporal association with cardiovascular events. Nat Commun. 2024; 15:4353. doi: 10.1038/s41467-024-48713-3.
  2. Iida H, Takegami Y, Sakai Y, Watanabe T, Osawa Y, Imagama S. Early surgery within 48 hours of admission for hip fracture did not improve 1-year mortality in Japan: a single-institution cohort study. Hip Int. 2024:11207000241248836. doi: 10.1177/11207000241248836.
  3. Mula V, Parikh S, Suresh S, Bottle A, Loeffler M, Alam M. Venous thromboembolism rates after hip and knee arthroplasty and hip fractures. BMC Musculoskelet Disord. 2020; 21:95. doi:10.1186/s12891-020-3100-4.
  4. Beauchamp-Chalifour P, Belzile ÉL, Michael R, et al. The risk of venous thromboembolism in surgically treated hip fracture: A retrospective cohort study of 5184 patients. Orthop Traumatol Surg Res. 2022; 108:103142. doi: 10.1016/j.otsr.2021.103142.

 

 

 

 

The Archives of Bone and Joint Surgery
Volume 13, Issue 5
May 2025
Pages 291-298

  • Receive Date 23 June 2024
  • Revise Date 24 December 2024
  • Accept Date 09 January 2025